Xilio Therapeutics, Inc. (XLO)
$0.81
+0.03
(+3.98%)▲
Live
Performance
- $0.79$0.83$0.81
2.48%
Downside
Day's Volatility :4.99%
Upside
2.58%
- $0.49$2.89$0.81
39.51%
Downside
52 Weeks Volatility :83.07%
Upside
72.01%
Returns
| Period | Xilio Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -21.23% | 3.6% | 0.0% |
6 Months | -29.18% | 10.2% | 0.0% |
1 Year | -58.64% | 19.6% | 0.0% |
3 Years | -95.13% | 16.8% | -23.0% |
Highlights
Market Capitalization | 34.7M |
Book Value | $0.76 |
Earnings Per Share (EPS) | -1.98 |
Wall Street Target Price | 5.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -622.57% |
Return On Assets TTM | -45.76% |
Return On Equity TTM | -130.03% |
Revenue TTM | 2.4M |
Revenue Per Share TTM | 0.05 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -56.8M |
EBITDA | -64.9M |
Diluted Eps TTM | -1.98 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.26 |
EPS Estimate Next Year | -0.58 |
EPS Estimate Current Quarter | -0.23 |
EPS Estimate Next Quarter | -0.4 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 579.01%
Technicals Summary
Sell
Neutral
Buy
Xilio Therapeutics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Xilio Therapeutics, Inc. | 3.07% | -29.18% | -58.64% | -95.13% | -95.13% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Xilio Therapeutics, Inc. | NA | NA | NA | -1.26 | -1.3 | -0.46 | NA | 0.76 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Xilio Therapeutics, Inc. | Buy | $34.7M | -95.13% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Xilio Therapeutics, Inc.
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 142.7%
Institutional Holdings
Bain Capital Life Sciences Investors, LLC
8.61%Rock Springs Capital Management LP
6.83%RiverVest Venture Management LLC
3.28%FMR Inc
3.18%Morgan Stanley - Brokerage Accounts
2.53%Vanguard Group Inc
2.05%
Company Information
xilio is a waltham, massachusetts-based biopharmaceutical company focused on defeating cancer. the company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, xilio, derived from the latin term, ex nihilo, meaning creation or big-bang. xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. to learn more, please visit www.xiliotx.com.
Organization | Xilio Therapeutics, Inc. |
Employees | 73 |
CEO | Dr. Rene Russo BCPS, Pharm.D. |
Industry | Services |
